NovaBay Pharmaceuticals, Inc. (NBY) - Utang jangka dawa marang modal

Despite global logistics risks and patent disputes, NovaBay Pharmaceuticals is successfully advancing its developments. Reviewing the long-term debt-to-equity chart on GURU.Markets, we see that the 0.25 metric determines this level. This is occurring as the company fights dependency on a single brand through new product lines, although profits remain based on demand for eyelid hygiene and online sales.

NovaBay Pharmaceuticals specializes in the sale of antiseptic and cosmetic skin and eye care products. This indicator is calculated as the ratio of liabilities with a maturity of more than one year to the total capital of the enterprise. It determines the extent to which business development depends on external long-term financing. It is critical for investors to assess this leverage to understand the company's financial autonomy. The trend of the long-term debt-to-equity ratio on this chart reflects the balance between investment growth and bankruptcy risks.